Smith & Nephew Snats (NPWA) AI Stock Analysis

2 Followers

Smith & Nephew Snats

(Frankfurt:NPWA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Margin and cash-flow recoveryImproving margins and strong cash generation indicate that efficiency actions are translating into more durable earnings quality. Maintaining profit, free cash flow, and ROIC targets despite slower revenue growth gives the company resources to fund innovation, investment, and shareholder returns.

Negative Factors

Slowing revenue growthLower revenue momentum limits near-term operating leverage and makes the company more dependent on cost savings to deliver earnings growth. The revised outlook also indicates that portfolio improvements and demand recovery may take longer to translate into broad-based sales acceleration.

Smith & Nephew Snats (NPWA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 12.99B
Dividend Yield: 2.50%
Average Volume (3M): 80
Price to Earnings (P/E): 20.2
Beta (1Y): 0.67
Revenue Growth: -1.20%
EPS Growth: 23.20%
Country: Germany
Employees: 18,362
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Smith & Nephew Snats Business Overview & Revenue Model

Company Description

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Me...

Smith & Nephew Snats Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:1.13%|Next Earnings Date:Mar 01, 2027

Earnings Call SentimentNeutral

The call painted a mixed picture: revenue growth came in below expectations, driven by weakness in U.S. Orthopaedics and reimbursement-related pressure in skin substitutes and bioactives. However, the company delivered strong profit and margin expansion, materially outperformed on efficiency savings (raising 2026 savings guidance), maintained trading profit, free cash flow and ROIC guidance, and highlighted multiple product and geographic growth drivers (notably in Sports Medicine & ENT, emerging markets, and a range of innovation milestones). Near‑term execution and reimbursement challenges create risk to topline momentum, but operational improvements and cost discipline have preserved earnings and cash targets.

Positive Updates

Strong profit performance and margin expansion

Trading profit of $566 million in H1, up $43 million year-on-year; trading margin expanded 60 bps to 18.3%, and gross margin improved 60 bps to 71.1%.

Negative Updates

Revenue growth below expectations

Q2 underlying revenue growth was 1.6% (revenue $1.6 billion) and H1 underlying growth 2.3% ($3.1 billion); management revised full‑year underlying revenue growth guidance to around 4% (H2 expected 5%–5.5%).

Company Guidance

Updated 2026 guidance: underlying revenue growth now expected around 4% for the year (H2 growth guided to 5.0–5.5% with Q3 roughly in line with Q1 and a Q4 step‑up ~6–7% — ADS just north of 5% due to an extra trading day); trading profit guidance is unchanged at around 8% growth excluding M&A (~$1.3bn trading profit including Integrity, with marginal dilution in 2026); free cash flow still expected at ~ $800m and ROIC >10%. Management has increased efficiency savings guidance from ~$150m to ~$200m (H1 delivered ~$133m, cumulative savings ~$330m, ~ $70m more expected in H2), tariffs are expected to be broadly neutral net of refunds, and the trading‑profit headwind from skin substitutes is now expected toward the upper end of the prior $20–$40m range. H1 metrics include revenue $1.6bn (Q2) and $3.1bn (H1), gross margin 71.1% (+60bps), trading profit $566m (+$43m, trading margin 18.3% +60bps), H1 trading cash flow $437m, H1 free cash flow $231m, cash conversion 77%, net debt ≈ $3.0bn (leverage ~1.8x EBITDA), $260m of a $500m buyback completed, and an interim dividend of $0.156/share (adjusted EPS H1 $0.477, +11%).

Smith & Nephew Snats Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:NPWA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	81Outperform	$129.95B	24.84	10.60%	2.81%	9.77%	12.28%
EW	76Outperform	$59.81B	59.78	9.69%	―	13.44%	-26.83%
SYK	75Outperform	$123.45B	33.73	15.61%	1.10%	7.87%	22.82%
ZBH	69Neutral	$20.31B	27.07	6.05%	0.89%	6.98%	-2.22%
BSX	64Neutral	$64.79B	19.04	13.87%	―	8.88%	25.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:NPWA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NPWA	Smith & Nephew Snats	27.60	-0.65	-2.32%
BSX	Boston Scientific	45.13	-59.85	-57.01%
EW	Edwards Lifesciences Corp.	105.81	19.70	22.88%
MDT	Medtronic	101.61	8.55	9.19%
SYK	Stryker Corp	318.79	-50.54	-13.68%
ZBH	Zimmer Biomet Holdings	107.47	17.86	19.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Smith & Nephew Snats AI Stock Analysis